Hot Products

Lapatinib (GW572016)
Catalog No: CFN60025

Lapatinib, used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively. Lapatinib induces ferroptosis and autophagic cell death.

Lappaol A
Catalog No: CFN95067

Lappaol A has antioxidant and antiaging properties, it may promote the C. elegans longevity and stress resistance through a JNK-1-DAF-16 cascade. Lappaol A also has potential chemosensitizing activity, it may be candidates for developing novel adjuvant anticancer agents.

Lappaol B
Catalog No: CFN95242

Reference standards.

Lappaol C
Catalog No: CFN95068

Lappaol C has antioxidant and antiaging properties, it may promote the C. elegans longevity and stress resistance through a JNK-1-DAF-16 cascade. Lappaol C also has potential chemosensitizing activity, it may be candidates for developing novel adjuvant anticancer agents.

Lappaol F
Catalog No: CFN95069

1. Lappaol F has antioxidant and antiaging properties, it may promote the C. elegans longevity and stress resistance through a JNK-1-DAF-16 cascade.
2. Lappaol F has potential chemosensitizing activity, it may be candidates for developing novel adjuvant anticancer agents.
3. Lappaol F exhibits antitumor activity in vitro and in vivo and has strong potential to be developed as an anticancer therapeutic.
4. Lappaol F strongly inhibited NO production in the LPS-stimulated RAW264.7 cells with the IC(50) value of 9.5 microM.

L-Arginine
Catalog No: CFN90550

L-Arginine is the nitrogen donor for synthesis of nitric oxide, a potent vasodilator that is deficient during times of sickle cell crisis. L-Arginine exhibits anti-atherosclerotic effect, L-arginine and soy enriched diet are effective in prevention of osteoporosis associated with diabetes mellitus. Exogenous L-Arginine could enhance neonate lymphocyte proliferation through an interleukin-2-independent pathway.

Lariciresinol
Catalog No: CFN98324

Lariciresinol is an enterolignan precursor, it possesses fungicidal activities by disrupting the fungal plasma membrane and therapeutic potential as a novel antifungal agent for the treatment of fungal infectious diseases in humans. Dietary lariciresinol can attenuate mammary tumor growth and reduce blood vessel density in human MCF-7 breast cancer xenografts and carcinogen-induced mammary tumors in rats.

Lariciresinol 4'-O-glucoside
Catalog No: CFN95400

Lariciresinol 4-O-glucoside
Catalog No: CFN95389

Lariciresinol acetate
Catalog No: CFN97679

Reference standards.